Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT



Financial Ratios:

currentRatio 8.172000
forwardPE 17.178465
debtToEquity 0.166000
earningsGrowth 0.183000
revenueGrowth 0.105000
grossMargins 0.592070
operatingMargins 0.319770
trailingEps 77.190000
forwardEps 100.300000

CAPLIPOINT's current ratio, being 8.172, means the company is well-positioned to meet its short-term debt obligations. This reflects CAPLIPOINT's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
CAPLIPOINT's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
CAPLIPOINT's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning CAPLIPOINT for continued success in the market.
CAPLIPOINT's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
CAPLIPOINT's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that CAPLIPOINT is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT

CAPLIPOINT's current price concerning projections presents no discernible risks or opportunities. This balanced situation suggests a period of stability, where investors might consider holding their positions until more information becomes available.

Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


Analysts have shown a buy bias for CAPLIPOINT, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to CAPLIPOINT, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.